Tonghua Dongbao Plans to Subscribe Up to 162 Million Yuan in Amoytop Biotech Convertible Bonds

Stock News

Jul 27

Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867) has announced its intention to participate in the subscription of convertible bonds issued by its associate company, Xiamen Amoytop Biotech Co., Ltd. (SHA: 688278).

According to the company's announcement, Amoytop Biotech plans to issue convertible bonds to unspecified investors, with a total fundraising amount not exceeding 1.533 billion yuan. Tonghua Dongbao will exercise its preemptive rights to subscribe for these bonds. The total investment principal for this subscription is capped at 162 million yuan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1159863253"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159863253\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159863253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159863253","market":"us","top_or_hot":-1,"title":"Tonghua Dongbao Plans to Subscribe Up to 162 Million Yuan in Amoytop Biotech Convertible Bonds","media":"Stock News","content":"<p><b>Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)</b> has announced its intention to participate in the subscription of convertible bonds issued by its associate company, <b>Xiamen Amoytop Biotech Co., Ltd. (SHA: 688278)</b>.<br><br>According to the company's announcement, Amoytop Biotech plans to issue convertible bonds to unspecified investors, with a total fundraising amount not exceeding 1.533 billion yuan. Tonghua Dongbao will exercise its preemptive rights to subscribe for these bonds. The total investment principal for this subscription is capped at 162 million yuan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tonghua Dongbao Plans to Subscribe Up to 162 Million Yuan in Amoytop Biotech Convertible Bonds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTonghua Dongbao Plans to Subscribe Up to 162 Million Yuan in Amoytop Biotech Convertible Bonds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-27 16:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867)</b> has announced its intention to participate in the subscription of convertible bonds issued by its associate company, <b>Xiamen Amoytop Biotech Co., Ltd. (SHA: 688278)</b>.<br><br>According to the company's announcement, Amoytop Biotech plans to issue convertible bonds to unspecified investors, with a total fundraising amount not exceeding 1.533 billion yuan. Tonghua Dongbao will exercise its preemptive rights to subscribe for these bonds. The total investment principal for this subscription is capped at 162 million yuan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FCEF","symbol_name":"First Trust Income Opportunities ETF","start_time":0,"source_url":"","article_id":"1159863253","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159863253","pubTimestamp":1785139464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867) has announced its intention to participate in the subscription of convertible bonds issued by its associate company, Xiamen Amoytop Biotech Co.,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600867":"通化东宝","688278":"特宝生物","FCEF":"First Trust Income Opportunities ETF","BK0239":"医药制造","BK0196":"行业龙头","BK0188":"融资融券","SABA":"Saba Capital Income & Opportunities Fund II"},"translate_title":"通化东宝计划认购至多1.62亿元的Amoytop生物可转换债券","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600867":1,"688278":1,"SABA":1,"FCEF":1},"content_text":"Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA: 600867) has announced its intention to participate in the subscription of convertible bonds issued by its associate company, Xiamen Amoytop Biotech Co., Ltd. (SHA: 688278).According to the company's announcement, Amoytop Biotech plans to issue convertible bonds to unspecified investors, with a total fundraising amount not exceeding 1.533 billion yuan. Tonghua Dongbao will exercise its preemptive rights to subscribe for these bonds. The total investment principal for this subscription is capped at 162 million yuan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}